DDInter1024 DDInter1676
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lapatinib {u} (Compound) treats {v} (Disease) breast cancer
Lapatinib {u} (Compound) binds {v} (Gene) TAP1
Lapatinib {u} (Compound) upregulates {v} (Gene) VAV3
Lapatinib {u} (Compound) downregulates {v} (Gene) PLOD3
Lapatinib {u} (Compound) causes {v} (Side Effect) Nail disorder
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Lapatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propofol
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Lapatinib {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Lapatinib (Compound) treats breast cancer (Disease)
Lapatinib (Compound) binds TAP1 (Gene)
Lapatinib (Compound) upregulates VAV3 (Gene)
Lapatinib (Compound) downregulates PLOD3 (Gene)
Lapatinib (Compound) causes Nail disorder (Side Effect)
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Lapatinib may cause a minor interaction that can limit clinical effects when taken with Donepezil
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Propofol
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lapatinib may lead to a major life threatening interaction when taken with Macimorelin